Cover image not available

Costing statement : Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma : Implementing NICE guidance

National Institute for Health and Clinical Excellence

Publication Data

Title Costing statement : Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma : Implementing NICE guidance
Alternative Title National costing statement : Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Author National Institute for Health and Clinical Excellence
Publisher National Institute for Health and Clinical Excellence
Publication date 0000
Publication location London

Descriptive Notes

"Technology appraisal implementation tools."

Topics

Melanoma :: Chemotherapy :: England :: Cost effectiveness
Monoclonal antibodies

Catalogue Data

OBNB ID GBB586305
ISBN 10 n/a
ISBN 13 n/a
Type BibliographicResource, Book
Dewey Classification 616.99477061

ISBD

P1053 1 online resource (4 pages).

Buy a copy

OBNB doesn't sell books, but you may be able to find a copy at one of these websites:

Costing statement : Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma : Implementing NICE guidance by National Institute for Health and Clinical Excellence. Published by National Institute for Health and Clinical Excellence. Publication and catalogue information, links to buy online and reader comments.